The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition multiple sclerosis (MS), the companies said on Monday. The companies were reviewing the content of the health regulator's so called complete response letter (CRL) and would soon determine the appropriate next steps, they said, without disclosing further details. Mapi Pharma did not immediately respond to Reuters requests for additional details on the contents of the CRL, which indicates that an application would not be approved in its present form and requires more information.
Viatris Inc (NASDAQ:VTRS) recently announced a dividend of $0.12 per share, payable on 2024-03-18, with the ex-dividend date set for 2024-03-08. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's delve into Viatris Inc's dividend performance and assess its sustainability.
Xiangyang Ni, President of Greater China at Viatris Inc (NASDAQ:VTRS), executed a sale of 21,532 shares in the company on March 4, 2024, according to a recent SEC filing.